ImmaticsIMTX
IMTX
About: Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Employees: 343
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
0% more funds holding
Funds holding: 90 [Q2] → 90 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
4% less capital invested
Capital invested by funds: $907M [Q2] → $869M (-$38.4M) [Q3]
1.89% less ownership
Funds ownership: 75.75% [Q2] → 73.86% (-1.89%) [Q3]
60% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 42
63% less call options, than puts
Call options by funds: $4.67M | Put options by funds: $12.7M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
174%
upside
Avg. target
$15
174%
upside
High target
$15
174%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Alex Stranahan 0% 1-year accuracy 0 / 1 met price target | 174%upside $15 | Buy Maintained | 19 Nov 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
3 weeks ago
New Strong Buy Stocks for January 9th
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Positive
Zacks Investment Research
3 weeks ago
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
2 months ago
What Makes Immatics (IMTX) a New Buy Stock
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
2 months ago
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Positive
Zacks Investment Research
2 months ago
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Seeking Alpha
3 months ago
Immatics: A Promising TCR Pipeline
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
Neutral
GlobeNewsWire
3 months ago
Immatics Announces Pricing of $150 Million Public Offering
H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount.
Negative
Benzinga
3 months ago
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.
Charts implemented using Lightweight Charts™